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Abstract
Background: Chlamydia pneumoniae (C pn) infection causes an acute inflammation in the respiratory system that
may become persistent, but little is known about the long-term respiratory effects of C pn infections. Aim: To
estimate the long term respiratory effects of C pn with change in forced expiratory volume in one second (FEV1)
and forced vital capacity (FVC) as a main outcome variable.
Methods: The study comprised of 1109 subjects (500 men and 609 women, mean age 28 ± 6 years) that
participated in the Reykjavik Heart Study of the Young. Spirometry and blood samples for measurements of IgG
antibodies for C pn were done at inclusion and at the end of the follow-up period (mean follow-up time 27 ± 4
years).
Results: Having IgG against C pn at both examinations was significantly associated to a larger decrease in FEV1
(6 mL/year) and FVC (7 mL/year) in women but not in men. In women the association between C pn and larger
FEV1 decline was only found in women that smoked at baseline where having C pn IgG was associated with 10
mL/year decline compared to smokers without C pn IgG. These results were still significant after adjustment for
age, smoking and change in body weight.
Conclusion: Our results indicate that persistent C pn serology is related to increased decline in lung function in
women but not in men. This effect was, however, primarily found in smoking women. This study is a further
indication that the pathophysiological process leading to lung impairment may differ between men and women.
Background
Chlamydia pneumoniae (C pn) is an intracellular gram-
negative pathogen that is detected in 5 to 10% of com-
munity-acquired pneumonia and other lower respiratory
tract infections [1] Most adults are infected at least once
during their lifetime, as indicated by seroprevalence of
70 to 80% [2]. C pn respiratory diseases may manifest as
an acute disease or persistent and recurring infection
that causes intense chronic inflammation. Growing evi-
dence indicates that inflammation results from cellular
responses by non immune cells, including mucosal
epithelial and vascular endothelial cells [3]. Studies have
suggested that C pn may be related to the pathogenesis
of wheeze in children [4], asthma in adults [5] and to
chronic obstructive pulmonary disease (COPD) [6]. Sys-
temic aspects of COPD include oxidative stress and
altered circulating levels of inflammatory mediators and
acute-phase proteins. C-reactive protein (CRP) reflects
the total systemic burden of inflammation in several dis-
orders and has been shown to up regulate the produc-
tion of proinflammatory cytokines [7]. Systemic
inflammation is increasingly being recognised as a risk
factor for a number of different complications including
atherosclerosis, cachexia, anorexia, and osteoporosis, but
all of these complications are commonly observed in
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ology and atherosclerosis [9] and ischemic heart diseases
have been reported, as well as an additive or synergistic
effect of other persistent infections on atherosclerosis
[10]. These cardiovascular associations with persistent
infections may be highly relevant in COPD since
ischemic heart disease and stroke are the leading causes
of mortality among patients with COPD [8].
Several studies have reported gender differences in the
association between risk factors and pulmonary diseases.
In one study of young children a positive serology for C
pn was related to wheeze in girls but not in boys [4].
Other studies have shown gender differences in the
association between various other risk factors and
changes in lung function such as smoking [11] and CRP
[12]. Most previous studies on the association of C pn
and respiratory diseases have been performed on patient
samples from different clinical settings, but large popu-
lation-based longitudinal studies are lacking. No studies
are available on the association between C pn serology
and long term changes in lung function.
The primary aim of the present research was to study
the association between C pn serology and changes in
lung function in a longitudinal population study with
particular focus on gender differences.
Methods
The Reykjavik Study of the Young
The Reykjavík Study of the Young was conducted in 3
stages between 1973 and 2003 and recruited 2147 parti-
cipants aged 25-62 years. Stages 1,2 and 3 took part in
the years: 1 (1973-1974); 2 (1983-1985); 3 (2001-2003).
The present research is based on a subset of the Reykja-
vik Study of the Young which consisted of a random
sample of individuals born in 1940 through 1954 who
were living in the greater Reykjavik in 1973. The aim of
the study was to compare younger generations to the
older ones who were being investigated in the Reykjavik
Study [12,13]
T h ep r e s e n ts t u d yf o c u s e so nt h ep u l m o n a r yp a r to f
the database, the methodology of which has been
described separately [13]. Only subjects who had partici-
pated both at baseline (either stage 1 or 2) and follow-
up (stage 3) were included in the present analysis. In
addition two serum samples and acceptable pulmonary
testing were needed. Altogether 1109 came for the fol-
low-up study in 2001-2003, of whom 962 had come for
the first stage in 1973-74 and 147 in 1983-85. The lung
function tests included measurements of forced expira-
tory volume in one second (FEV1) and forced vital capa-
city (FVC).
Smoking status was recorded at each survey. Partici-
pants were divided into never smokers at baseline, cur-
rent or ex-smokers, and the number of pack years was
calculated. Body mass index (BMI) was calculated as
weight in kilograms divided by the square of height in
meters.
Serologic methods
IgG antibodies against Chlamydia pneumoniae (C pn)
were measured using reagents from the Immuno Biolo-
gical Laboratories, Hamburg, Germany. Serum samples
that gave indefinite results in antibody measurements
were classified as seronegative.
Statistics
Statistical analyses were performed using STATA 9
software (Stata Corp., Texas, USA). The Chi
2 test
a n du n p a i r e dtt e s tw e r eu s e dt oc o m p a r ec h a r a c t e r -
istics between men and women. Multiple linear
regression was used to analyse the association
between lung function and C pn IgG status. A
p-value < 0.05 was considered as statistically signifi-
cant. In these regression analyses change in FEV1 and
FVC from baseline to follow up (mL/year) was used
as the dependent variable. The analyses were strati-
fied by sex and the following independent variables
were included: age (mean age between the surveys),
age
2, height, BMI, change in BMI and pack years
between the surveys.
Ethics
Approval was obtained from The National Bioethics
Committee and The Data Protection Authority in
Iceland
Results
The characteristics of the study population are pre-
sented in Table 1. Women were more likely to be smo-
kers at baseline and had a higher smoking exposure
during the follow-up. Women were leaner at baseline
but had a larger increase in BMI during the follow-up
period. Men were more likely to have IgG antibodies
against C pn at both surveys (Figure 1).
C pn serology and change in lung function
Women with C positive C pn serology at both examina-
tions had a larger decline in FEV1 and FVC than
women with negative C pn serology, while no corre-
sponding association was found in men. Women that
developed positive C pn serology during the follow-up
had a significantly larger decline in FVC, whereas the
corresponding association to FEV1 was of border-line
significance (p = 0.06) (Table 2). Decline in lung func-
tion was associated with an increase in BMI and smok-
ing in both men and women, while a higher baseline
BMI was associated with a greater decline in FVC but
not in FEV1.
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The sex difference in association between change in
lung function and C pn serology was statistically signifi-
cant for FEV1 (pinteraction = 0.04) and almost significant
for FVC (pinteraction = 0.08). A significant interaction was
found between women that were non-smokers and smo-
kers at baseline (pinteraction = 0.02). Women that were
smokers had a significantly larger decline in lung func-
tion if they had a positive C pn serology at the second
or at both examinations (Figure 2). No such correspond-
ing interaction was found for men (Figure 3). No inter-
actions were found concerning the association between
C pn and FVC. No interactions were found for BMI or
birth cohort concerning the association between C pn
and change in lung function.
Discussion
The main result of the study was that C pn infections
were associated with increased lung function decline.
This finding was, however, only seen in women. This
study thereby provides further evidence of sex differ-
ences in the mechanisms related to decline in lung func-
tion. Our study also indicates that C pn may enhance
the lung damaging effect of smoking in women.
The main strength of our study is that it is a popula-
tion-based longitudinal study with a follow-up of 27
years. A potential weakness is that IgG antibodies mea-
sured by ELISA were used as the only indicator of per-
sistent infection with C pn. Previous studies have shown
that high levels of IgG antibodies to C pn measured by
ELISA do not persist for half a decade after
Table 1 Characteristics of the participants (% and mean ± SD)
Men
(n = 500)
Women
(n = 609)
p-value All
(n = 1109)
Age at baseline 27.9 ± 5.7 27.4 ± 5.4 0.15 27.6 ± 5.6
Smoking history (%) < 0.0001
never 41.8 41.5 41.7
ex 23.6 14.1 18.4
current 34.6 44.3 40.0
Pack years between surveys in current smokers 14.7 ± 13.1 17.0 ± 12.5 0.04 15.8 ± 12.9
BMI kg/m2 23.2 ± 2.8 22.0 ± 3.1 < 0.0001 22.5 ± 3.0
Change in BMI over 10 yrs. 1.5 ± 1.2 1.9 ± 1.3 < 0.0001 1.7 ± 1.3
Figure 1 Proportion men and women divided after Chlamydia pneumoniae (C pn) serology at baseline and follow-up.
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In young military recruits IgG antibody levels measured
by microimmunofluorescence test decrease rapidly after
the infection [15]. The microimmunofluorescence test is
however not suitable for seroepidemiological studies.
Two studies have demonstrated that the ELISA test has
comparable sensitivity and specificity to the microimmu-
nofluorescence technique [14,16]. Another possible
weakness is that our study population was not assessed
by post-bronchodilator lung function testing and we can
not know how much of the decline in FEV1 was due to
reversible (asthma) or irreversible airflow obstruction
(COPD). The widespread use of postbronchodilator
spirometry is mostly confined to the twenty-first cen-
tury. The long follow-up time of our study population
is, however, unique.
The finding that C pn infections are more strongly
related to lung impairment in women than in men fit
surprisingly well with data from children where an
association between wheeze and C pn IgG was stronger
in girls than in boys [4]. There are several reports on
gender differences in the association between wheezing
and asthma irrespective of C pn or other infections. The
predominant trend reported is a greater incidence of
wheezing and asthma in boys with a reversal between
ages 10-20 when the incidence becomes greater in
females [17-22]. Girls are reported to be more vulner-
able than boys to the impact of smoking and overweight
on respiratory symptoms and lung function [23]. In con-
trast to the findings in children, Chinn et al found that
weight gain had a larger effect in men than in women
[11]. A stronger association between systemic inflamma-
tion and lung function decline in men than in women
has also been reported in several studies [12,24,25]. Sev-
eral mechanisms have been suggested to explain these
gender differences. The sexes may develop their airway
disease based on different sex related genetics[26] or on
different immunological time scales [27]. Female sex
Table 2 Association between C pn serology and change in FEV1 and FVC (mL/year) in men and women
Men Women
FEV1 FVC FEV1 FVC
C pn only at follow up -1.8 (-11, 7.5) -7.0 (-16, 2.5) -5.6 (-11, 0.3) -7.4 (-12, -2.6)
C pn only at baseline 2.6 (-5.0, 10) -1.4 (-9.1, 6.3) -0.5 (-5.9, 5.0) -1.6 (-6.0, 2.8)
C pn at both examinations 2.1 (-2.9, 7.0) -0.3 (-5.3, 4.8) -4.5 (-8.2, -0.7) -4.4 (-7.5, -1.3)
BMI at baseline
(per 5 units)
0.6 (-2.6, 3.9) -5.1 (-8.5,-1.8) -1.1 (-3.5, 1.3) -4.3 (-6.2, -2.3)
ΔBMI (per 10 years) -2.1 (-3.5, -0.4) -5.3 (-6.9, -3.7) -2.2 (-3.2, -1.1) -2.8 (-3.6, -1.9)
Pack years between surveys (per 10 units) -2.1 (-3.5, -0.7) -3.0 (-4.4, -1.5) -1.6 (-2.7, -0.5) -2.0 (-2.9, -1.0)
The estimates are adjusted for the variables in the table and age, height and BMI.
Figure 2 Association between Chlamydia pneumoniae (C pn) serology and change in FEV1 (mL/year) in women that are non-smokers
or current smokers. The estimates are adjusted for age, height, smoking (pack years), BMI and change in BMI. Participants that were C pn
negative at both surveys are the reference group in each smoking status group.
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gender difference as there is increasing evidence that
sex hormones play a role in lung function development
and decline. For an instance, it has been recently bee
reported that girls with an early menarche have lower
lung function as adults [28].
There are reports on a positive association of C pn
and IgA and IgG serology and COPD [29,30] but nega-
tive associations have also been reported [31]. A causal
association between C pn and COPD has, therefore, not
been proven and possible mechanisms are not clear[32].
In a recent experimental study an intranasal inoculation
with C. pneumoniae on day 0 was from day 7 associated
with both sustained bronchial hyper-responsiveness and
airway inflammation in mice [33]. An association
between bronchial hyperresponsiveness and IgA antibo-
dies against C pn has also been found in Swedish popu-
lation study [34]. Acute in vitro experiments of human
lung tissue with C pn suggest that C pn plays different
roles during acute and chronic stages of pulmonary
infection [35].
If persistent C pn infections play a significant role in
the pathogenesis of asthma, COPD and lung function
decline, this opens the therapeutic possibility of useful
antibiotic treatment The data supporting antibiotic ther-
apy are limited, however, as shown in a Cochrane review
o fm a c r o l i d eu s a g ei nt r e a t m e n to fc h r o n i ca s t h m a[ 3 6 ]
and further long term studies are needed to confirm the
possible role of persistent infections in the decline in
lung function.
Conclusion
In conclusion, our results indicate that persistent C pn
serology is related to increased decline in lung function
in women but not in men. This effect was, however, pri-
marily found in smoking women. This study is a further
indication that the pathophysiological process leading to
lung impairment may differ between men and women.
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Figure 3 Association between Chlamydia pneumoniae (C pn) serology and change in FEV1 (mL/year) in men that are non-smokers or
current smokers. The estimates are adjusted for age, height, smoking (pack years), BMI and change in BMI. Participants that were C pn
negative at both surveys are the reference group in each smoking status group.
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